Convention Sectors convene Convention Member representatives around common areas of focus to share insights, learn from each other, provide input to USP, and to collaborate on priority topics. Sector convenings provide interactive programming, including panel discussions with guest speakers from industry, FDA, patient groups, practitioner perspectives, and more; Member presentations about recent programs and priorities; updates on USP work; and group dialogue. As one of USP’s governing bodies, it is invaluable for USP staff to hear input from Members on work, plans, and progress, and the Sectors are one forum for that important contribution.
Any Convention Member Organization representative is welcome to participate – the Delegate to the USP Convention, and other staff or members of that organization interested in one or more Sector areas. Each Sector is chaired by a Convention Member representative who is leader in that space; they help shape Sector programming and activities. The Chair also serves on the USP Council of the Convention, bringing back to this leadership body, Member insights and recommendations.
Recent Sector engagements have included:
- Biologics Sector convened around the quality of genomic data and biosimilar quality
- Generic Medicines and Healthcare Practice Sectors met jointly to address quality across the healthcare continuum and advancing access to quality generic medicines and patient care
- Dietary Supplements Sector considered ways to support the practitioner – consumer discussion about quality of dietary supplements
- Multiple Sectors convened during the three-part Convention Exchange Series on Ensuring a Resilient Supply Chain: A Shared Imperative to share their diverse perspectives, expertise, and insights about the barriers and potential solutions to global pharmaceutical supply chain vulnerabilities. The summary report provides discussion highlights, updates on related USP initiatives, such as the Medicine Supply Map and the launch of the USP Advanced Manufacturing Technology Lab, as well as recommendations to support resiliency in multiple stages of the medicines supply chain.
